Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VLI · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Patients are dosed on Day 1 and Day 8 of a 21-day cycle. |
| 2 | EXPERIMENTAL | Patients are dosed on Day 1 of a 21-day cycle. |
| Name | Type | Description |
|---|---|---|
| VLI | DRUG | Patients are dosed on Day 1 and Day 8 of a 21-day cycle. |
Inclusion Criteria: 1. Histologically confirmed solid tumor refractory to standard therapy or for which no standard therapy is known to exist, or relapsed and/or refractory non-Hodgkin's lymphoma or Hodgkin's disease 2. Adequate hematologic, hepatic and renal functions as defined by laboratory test...
Top 20 of 45 competitors
VLI is an investigational small molecule being developed for the treatment of tumors, including solid tumors, Hodgkin's disease, and non-Hodgkin's lymphoma. It is currently in Phase 1 clinical development and has not been approved by the FDA.
VLI is being developed by Assertio Holdings, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ASRT. The drug is currently in Phase 1 clinical development for oncology indications.
VLI is in Phase 1 clinical development. One Phase 1 trial has been completed, and the drug remains investigational. It has not received FDA approval and is not yet available as a marketed therapy.
VLI has been studied in one completed Phase 1 clinical trial, NCT00364676, which evaluated the drug in patients with advanced solid tumors, non-Hodgkin's lymphoma, or Hodgkin's disease. The trial enrolled 67 participants in the United States and Canada.
Yes, VLI refers to vinorelbine liposomes injection. The completed Phase 1 trial, NCT00364676, was titled 'Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease' and enrolled 67 patients.